cardiomyopathy, independent of coronary artery disease. This so-called "diabetic cardiomyopathy" is characterised histologically by myocardial fibrosis with reduced myocardial elasticity, impaired contractility and overt cardiac dysfunction. Accordingly, strategies that reduce the pathological accumulation of extracellular matrix have been advocated as potential therapies for the treatment and prevention of heart failure in both diabetic and nondiabetic states.

[0006] Current treatment of chronic heart failure focuses on the modulation of the neurohormonal activation that typically develops in response to the evolving functional abnormalities. However, despite such therapy, frequently used in combination, cardiac dysfunction continues to progress in the majority of patients. Given the importance of pathological fibrosis in adverse cardiac remodelling, a potential role of antifibrotic agents has been suggested. Studies conducted over more than a decade have consistently indicated a major role for the prosclerotic growth factor, transforming growth factor-β (TGF-β) in organ fibrosis and dysfunction, such that blockade of its expression and action represent an important therapeutic target.

[0007] Tranilast has also been shown to reduce inflammation in allergic diseases, such as allergic rhinitis and bronchial asthma, etc., and have anti-proliferative activity.

[0008] However, it has recently been shown that genetic factors in certain patients, specifically a Gilbert's syndrome UGT1A1 variant, confers susceptibility to tranilast-induced hyperbilirubinemia. Such hyperbilirubinemia may be associated with tranilast itself or the formation, *in vivo*, of the following tranilast metabolite,



.

[0009] An ongoing need exists to identify and provide drugs with potential anti-fibrotic, anti-inflammatory, and anti-proliferative or anti-neoplastic activity for the treatment or prevention of diseases associated with fibrosis, diseases characterized by inflammation and neoplastic disease (both benign and malignant), and as alternatives/adjuncts to tranilast.

SUMMARY

[0009a] In one aspect, the present disclosure refers to a compound of Formula **I**:



I,

or a pharmaceutically acceptable salt thereof; wherein

T is  ;

X is O;

Y is O;

Z is a bond;

R^1 is C_{2-4} alkynyl;

R^2 is C_{1-4} alkyl;

R^3 is hydrogen, alkyl, alkynyl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein R^3 is optionally substituted with $-NR^aR^b$ or alkyl;

R^4 and R^5 are hydrogen;

each occurrence of R^6 is, independently, F, Cl, or Br;

G is hydrogen;

m is 1 or 2; and

each occurrence of R^a and R^b is, independently, hydrogen, acyl, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, heterocyclyl, $C(O)OC_{1-6}$ alkyl, $C(O)C_{1-6}$ alkyl, or R^a and R^b together with the atoms to which they are attached form a heterocyclyl ring.

[0009b] In another aspect, the present disclosure refers to a compound of Formula **I**:



I,

or a pharmaceutically acceptable salt thereof; wherein

T is  ;

X is O;

Y is O;

Z is a bond;

R^1 is C_{2-4} alkynyl;

R^2 is C_{1-4} alkyl;

R^3 is hydrogen, alkyl, alkynyl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein R^3 is optionally substituted with $-NR^aR^b$ or alkyl;

R^4 and R^5 are hydrogen;

G is $C(O)R^7$;

R^7 is NHR^9;

m is 0;

R^9 is tetrazolyl, pyridinyl, pyrazolyl, imidazolyl, or triazolyl, each of which is optionally substituted with up to two alkyl groups; and

each occurrence of R^a and R^b is, independently, hydrogen, acyl, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, heterocyclyl, $C(O)OC_{1-6}$ alkyl, $C(O)C_{1-6}$ alkyl, or R^a and R^b together with the atoms to which they are attached form a heterocyclyl ring.

[0009c] In another aspect, the present disclosure refers to a compound of Formula **I-i**:



I-i,

or a pharmaceutically acceptable salt thereof; wherein

X is O or NR^{10};

Y is O or NR^{10};

each occurrence of R^g and R^h is, independently, hydrogen or alkyl, or R^g and R^h together with the carbon atom to which they are attached form a carbonyl;

t is 1 or 2; and

each occurrence of R^{10} is, independently, hydrogen or C_{1-4} alkyl.

[0009d] In another aspect, the present disclosure refers to a compound selected from the group consisting of:

(E)-N-(2-fluorophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (1);

(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(5-methyl-1H-1,2,4-triazol-3-yl)phenyl)acrylamide (2);

(E)-N-(2-chlorophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (3);

(E)-N-(2-bromophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (4);

(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(o-tolyl)acrylamide (5);

(E)-N-(2-cyanophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (6);

(E)-N-(3,4-dichlorophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (7);

(E)-N-(2-(2H-tetrazol-5-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (16);

(E)-N-(2-(1,2,4-oxadiazol-3-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (17);

(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)-acrylamide (18);

(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)acrylamide (19);

(E)-N-(2-(1,2,4-oxadiazol-5-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (20);

(E)-N-(2-(1,3,4-oxadiazol-2-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (21);

(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(1-methyl-1H-pyrazol-4-yl)phenyl)-acrylamide (22);

(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)acryl-amide (23);

(E)-N-(2-(1H-pyrazol-4-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (24);

(E)-N-(2-(1H-imidazol-4-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (25);

(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide (26);

(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(methylsulfonyl)benzamide (27);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)acryl-amide (28);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-acrylamide (29);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2H-tetrazol-5-yl)benzamide (31);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(1-methylpiperidin-4-yl)benzamide (36);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(oxetan-3-yl)benzamide (38);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(pyridin-4-yl)benzamide (44);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(1-methyl-1H-pyrazol-4-yl)benzamide (47);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(1-methyl-1H-pyrazol-3-yl)benzamide (48);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(piperidin-4-yl)benzamide (49);
(E)-2-(3-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamido)benzoic acid (51);
(E)-N-(3-cyanophenyl)-3-[2-[2-(dimethylamino)ethoxy]-3-methoxy-4-prop-2-ynoxy-phenyl]prop-2-enamide (76);
((E)-N-(2-cyanophenyl)-3-(2-(2-(dimethylamino)ethoxy)-3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (77);
(E)-2-(3-(2-(2-(dimethylamino)ethoxy)-3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-benzoic acid (78);
(E)-N-(2-cyanophenyl)-3-[3-methoxy-2-(1-methylazetidin-3-yl)oxy-4-prop-2-ynoxy-phenyl]prop-2-enamide (79);
2-[[(E)-3-(3-methoxy-4-prop-2-ynoxy-2-pyrrolidin-3-yloxyphenyl)prop-2-enoyl]amino]benzoic acid (80);
(E)-N-(2-cyanophenyl)-3-[3-methoxy-2-(1-methylpyrrolidin-3-yl)oxy-4-prop-2-ynoxy-phenyl]prop-2-enamide (81);

(E)-N-(2-cyanophenyl)-3-(3-methoxy-4-prop-2-ynoxy-2-pyrrolidin-3-yloxy-phenyl)prop-2-enamide (82);
2-[[(E)-3-[3-methoxy-2-(4-piperidyloxy)-4-prop-2-ynoxy-phenyl]prop-2-enoyl]amino]benzoic acid (83);
2-[[(E)-3-[3-methoxy-2-(2-morpholinoethoxy)-4-prop-2-ynoxy-phenyl]prop-2-enoyl]amino]benzoic acid (84);
(E)-N-(2-cyanophenyl)-3-[3-methoxy-2-(2-morpholinoethoxy)-4-prop-2-ynoxy-phenyl]prop-2-enamide (85);
2-[[(E)-3-[2-[3-(dimethylamino)propoxy]-3-methoxy-4-prop-2-ynoxy-phenyl]prop-2-enoyl]amino]benzoic acid (86);
(E)-N-(2-cyanophenyl)-3-[2-[3-(dimethylamino)propoxy]-3-methoxy-4-prop-2-ynoxy-phenyl]prop-2-enamide (87);
(E)-N-(2-cyanophenyl)-3-[3-methoxy-2-(4-piperidyloxy)-4-prop-2-ynoxy-phenyl]prop-2-enamide (88);
(E)-N-(2-cyanophenyl)-3-[3-methoxy-2-[(1-methyl-4-piperidyl)oxy]-4-prop-2-ynoxy-phenyl]prop-2-enamide (89);
2-[[(E)-3-[4-(cyclopropylmethoxy)-2-[2-(dimethylamino)ethoxy]-3-methoxy-phenyl]prop-2-enoyl]amino]benzoic acid (90);
(E)-N-(3-cyanophenyl)-3-(2-(2-(dimethylamino)ethoxy)-3-methoxyphenyl)acrylamide (91);
(E)-N-(2-cyanophenyl)-3-(2-(2-(dimethylamino)ethoxy)-3-methoxyphenyl)acrylamide (92);
(E)-N-(3-cyanophenyl)-3-(2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamide (93);
(E)-N-(2-cyanophenyl)-3-[2-[2-(dimethylamino)ethoxy]-4-methoxy-phenyl]prop-2-enamide (94);
(E)-2-(3-(3,4-dimethoxy-2-(prop-2-yn-1-yloxy)phenyl)acrylamido)benzoic acid (95);
(E)-2-(3-(3,4-dimethoxy-2-(pyridin-3-ylmethoxy)phenyl)acrylamido)benzoic acid (96);
(E)-2-(3-(3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)acrylamido)benzoic acid (97);
(E)-2-(3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamido)benzoic acid (98);
(E)-2-(3-(3-methoxy-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamido)benzoic acid (99);
(E)-2-(3-(4-methoxy-3-morpholinophenyl)acrylamido)benzoic acid (101);
(E)-2-(3-(3-methoxy-4-morpholinophenyl)acrylamido)benzoic acid (103);

(E)-2-(3-(4-methoxy-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamido)benzoic acid (104);

2-[[(E)-3-(4-methyl-2,3-dihydro-1,4-benzoxazin-6-yl)prop-2-enoyl]amino]benzoic acid (107);

(E)-N-(2-(1,2,4-oxadiazol-5-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (108);

(E)-2-(3-(4-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)acrylamido)benzoic acid (109);

(E)-2-(3-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)acrylamido)benzoic acid (110);

(E)-2-(3-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acrylamido)benzoic acid (111);

(E)-2-(3-(4-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acrylamido)benzoic acid (112);

(E)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-acrylamide (114);

(E)-2-(3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)acrylamido)benzoic acid (116);

(E)-4-chloro-2-(3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)acrylamido)benzoic acid (117);

(E)-N-(4-fluorophenyl)-3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamide (120);

N-(4-cyanophenyl)-2-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)cyclopropane carboxamide (121);

2-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)-N-(4-fluorophenyl)cyclopropane-1-carboxamide (122);

(E)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-fluorophenyl)acrylamide (123);

(*E*)-*N*-(4-cyanophenyl)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (124);

(E)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)-N-(4-fluorophenyl)acrylamide (125);

(E)-3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)-N-(2-fluorophenyl)acrylamide (127);

(E)-3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)-N-(4-fluorophenyl)acrylamide (128);

(E)-N-(4-cyanophenyl)-3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)acrylamide (129);

(E)-2-(3-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)acrylamido)benzoic acid (130);

(E)-N-(4-cyanophenyl)-3-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide (131);

(E)-N-(4-fluorophenyl)-3-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide (132);

N-(4-fluorophenyl)-2-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)cyclopropanecarboxamide (133);
N-(4-cyanophenyl)-2-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)cyclopropanecarboxamide (135);
N-(4-fluorophenyl)-2-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)cyclopropane-1-carboxamide (136);
N-(4-cyanophenyl)-2-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)cyclopropane-1-carboxamide (137);
N-(2-fluorophenyl)-2-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)cyclopropane carboxamide (138);
(E)-N-(4-cyanophenyl)-3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamide (139);
(E)-3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-N-(2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)acrylamide (140);
(E)-N-(2-fluorophenyl)-3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamide (141);
N-(4-fluorophenyl)-2-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)cyclopropane carboxamide (143);
2-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-N-(2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)cyclopropanecarboxamide (144);
N-(2-fluorophenyl)-2-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)cyclopropane carboxamide (145);
(E)-N-(3-chlorophenyl)-3-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)acrylamide (147);
N-(3-chlorophenyl)-2-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)cyclopropane-1-carboxamide (148);
N-(4-chlorophenyl)-2-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)cyclopropane-1-carboxamide (149);
(E)-N-(3-chlorophenyl)-3-(4-methoxy-3-morpholinophenyl)acrylamide (151);
(E)-N-(2-chlorophenyl)-3-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)acrylamide (152);
(E)-N-(4-chlorophenyl)-3-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)acrylamide (153);

N-(4-chlorophenyl)-2-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)cyclopropane-1-carboxamide (154);
N-(2-chlorophenyl)-2-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)cyclopropane-1-carboxamide (155);
N-(3-chlorophenyl)-2-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)cyclopropane-1-carboxamide (156);
N-(2-chlorophenyl)-2-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)cyclopropane-1-carboxamide (157);
2-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)-N-(3-(methylsulfonyl)phenyl) cyclopropane-1-carboxamide (158);
(E)-N-(2-chlorophenyl)-3-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)acrylamide (159);
(E)-N-(3-chlorophenyl)-3-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)acrylamide (160);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-phenylacrylamide (8);
methyl (E)-1-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acryloyl)-1,2,3,4-tetrahydroquinoline-4-carboxylate (9)
(E)-1-(3,4-dihydroquinolin-1(2H)-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (10);
(E)-1-(3,4-dihydroquinoxalin-1(2H)-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (11);
(E)-1-(2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (12);
(E)-N-((trans)-2-aminocyclohexyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (13);
(E)-1-(4-hydroxy-3,4-dihydroquinolin-1(2H)-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (14);
(E)-1-(3-hydroxy-1H-indazol-1-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (15);
(E)-N-(2-(dimethylamino)ethyl)-2-(3-(3-methoxy-4-(prop-2-yn 1yloxy) phenyl) acrylamido) benzamide (30);

(E)-N-(3-(dimethylamino)propyl)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido) benzamide (32);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2-methoxyethyl)benzamide (33);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzamide (34);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2-morpholino ethyl)benzamide (35);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-((1-methylpiperidin-4-yl)methyl)benzamide (37);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-((tetrahydrofuran-3-yl)methyl)benzamide (39);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-((1-methyl-1H-imidazol-5-yl)methyl)benzamide (40);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(pyridin-2-ylmethyl)benzamide (41);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2-(pyridin-2-yl)ethyl)benzamide (42);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(pyridin-3-ylmethyl)benzamide (43);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(pyridin-4-ylmethyl)benzamide (45);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2-(pyridin-4-yl)ethyl)benzamide (46);
(E)-2-(3-(3-methoxy-4-(piperidin-4-ylmethoxy)phenyl)acrylamido)benzoic acid (50);
(E)-2-(3-(4-((3,5-dimethylisoxazol-4-yl)methoxy)-3-methoxyphenyl)acrylamido)benzoic acid (52);
(E)-2-(3-(3-methoxy-4-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)acrylamido)benzoic acid (53);
(E)-2-(3-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)acrylamido)benzoic acid (54);
(E)-2-(3-(3-methoxy-4-(2-(pyridin-2-yl)ethoxy)phenyl)acrylamido)benzoic acid (56);

(E)-2-(3-(3-methoxy-4-(2-(pyridin-3-yl)ethoxy)phenyl)acrylamido)benzoic acid (57);
(E)-2-(3-(3-methoxy-4-(2-(pyridin-4-yl)ethoxy)phenyl)acrylamido)benzoic acid (59);
(E)-2-(3-(3-methoxy-4-((1-methyl-1H-pyrazol-5-yl)methoxy)phenyl)acrylamido)benzoic acid (60);
(E)-2-(3-(4-methoxy-3-(2-methoxyethoxy)phenyl)acrylamido)benzoic acid (61);
(E)-2-(3-(4-methoxy-3-(2-(pyridin-2-yl)ethoxy)phenyl)acrylamido)benzoic acid (62);
(E)-2-(3-(4-methoxy-3-(pyridin-3-ylmethoxy)phenyl)acrylamido)benzoic acid (63);
(E)-2-(3-(4-methoxy-3-(2-(pyridin-3-yl)ethoxy)phenyl)acrylamido)benzoic acid (64);
(E)-2-(3-(4-methoxy-3-(2-(pyridin-4-yl)ethoxy)phenyl)acrylamido)benzoic acid (65);
(E)-2-(3-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)acrylamido)benzoic acid (66);
(E)-2-(3-(4-methoxy-3-((1-methyl-1H-pyrazol-5-yl)methoxy)phenyl)acrylamido)benzoic acid (67);
(E)-2-(3-(3-methoxy-4-((4-methylpiperazin-1-yl)methyl)phenyl)acrylamido)benzoic acid (68);
(E)-2-(3-(3-methoxy-4-(morpholinomethyl)phenyl)acrylamido)benzoic acid (69);
(E)-2-(3-(4-methoxy-3-(((1-methylpiperidin-4-yl)oxy)methyl)phenyl)acrylamido)benzoic acid (70)
(E)-2-(3-(4-methoxy-3-((prop-2-yn-1-yloxy)methyl)phenyl)acrylamido)benzoic acid (71);
(E)-2-(3-(3-methoxy-4-((prop-2-yn-1-yloxy)methyl)phenyl)acrylamido)benzoic acid (72);
(E)-2-(3-(4-methoxy-3-(methoxymethyl)phenyl)acrylamido)benzoic acid (73);
(E)-2-(3-(4-methoxy-3-((prop-2-yn-1-ylamino)methyl)phenyl)acrylamido)benzoic acid (74);
(E)-2-(3-(3-methoxy-4-((prop-2-yn-1-ylamino)methyl)phenyl)acrylamido)benzoic acid (75);
(E)-2-(3-(4-ethyl-3-methoxyphenyl)acrylamido)benzoic acid (100);
2-[[(E)-3-[4-(cyclopropylmethyl)-3-methoxyphenyl]prop-2-enoyl]amino]benzoic acid (102);
(E)-2-(3-(3-ethyl-4-methoxyphenyl)acrylamido)benzoic acid (105);
(E)-2-(3-(3-(cyclopropylmethyl)-4-methoxyphenyl)acrylamido)benzoic acid (106);
(E)-1-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (113);
(E)-1-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)-prop-2-en-1-one (115);

(E)-1-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-3-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)prop-2-en-1-one (118);
(2H-benzo[b][1,4]oxazin-4(3H)-yl)(2-(3-methoxy-4-(prop-2-yn-1-yloxy) phenyl) cyclopropyl) methanone (119);
(E)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)-1-(3-hydroxy-1H-indazol-1-yl)prop-2-en-1-one (126);
(3-hydroxy-1H-indazol-1-yl)(2-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)cyclopropyl) methanone (134);
(E)-1-(3-hydroxy-1H-indazol-1-yl)-3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)prop-2-en-1-one (142);
(3-hydroxy-1H-indazol-1-yl)(2-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl) cyclopropyl)methanone (146);
(E)-3-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)-N-(pyridin-3-yl)acrylamide (150); and pharmaceutically acceptable salts thereof.

[0009e] In yet another aspect, the present disclosure refers to a pharmaceutical composition comprising the compound as disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0009f] In yet another aspect, the present disclosure refers to a pharmaceutical composition comprising the compound as disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for use in therapy.

[0009g] In yet another aspect, the present disclosure refers to the use of the pharmaceutical composition comprising the compound as disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier in the manufacture of a medicament for treating a disease or condition associated with fibrosis in a subject in need thereof.

[0010] In one example, provided are compounds of Formula **I**:

N-(4-chlorophenyl)-2-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)cyclopropane-1-carboxamide (154);

N-(2-chlorophenyl)-2-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)cyclopropane-1-carboxamide (155);

N-(3-chlorophenyl)-2-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)cyclopropane-1-carboxamide (156);

N-(2-chlorophenyl)-2-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)cyclopropane-1-carboxamide (157);

2-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)-N-(3-(methylsulfonyl)phenyl) cyclopropane-1-carboxamide (158);

(E)-N-(2-chlorophenyl)-3-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)acrylamide (159);

(E)-N-(3-chlorophenyl)-3-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)acrylamide (160); and pharmaceutically acceptable salts thereof.

[0012] In another example, provided are the following compounds:

(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-phenylacrylamide (8);

methyl (E)-1-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acryloyl)-1,2,3,4-tetrahydroquinoline-4-carboxylate (9)

(E)-1-(3,4-dihydroquinolin-1(2H)-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (10);

(E)-1-(3,4-dihydroquinoxalin-1(2H)-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (11);

(E)-1-(2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (12);

(E)-N-((trans)-2-aminocyclohexyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (13);

(E)-1-(4-hydroxy-3,4-dihydroquinolin-1(2H)-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (14);

(E)-1-(3-hydroxy-1H-indazol-1-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (15);

(E)-2-(3-(4-ethyl-3-methoxyphenyl)acrylamido)benzoic acid (100);

2-[[(E)-3-[4-(cyclopropylmethyl)-3-methoxyphenyl]prop-2-enoyl]amino]benzoic acid (102);

(E)-2-(3-(3-ethyl-4-methoxyphenyl)acrylamido)benzoic acid (105);

(E)-2-(3-(3-(cyclopropylmethyl)-4-methoxyphenyl)acrylamido)benzoic acid (106);

(E)-1-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (113);

(E)-1-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)-prop-2-en-1-one (115);

(E)-1-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-3-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)prop-2-en-1-one (118);

(2H-benzo[b][1,4]oxazin-4(3H)-yl)(2-(3-methoxy-4-(prop-2-yn-1-yloxy) phenyl) cyclopropyl) methanone (119);

(E)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)-1-(3-hydroxy-1H-indazol-1-yl)prop-2-en-1-one (126);

(3-hydroxy-1H-indazol-1-yl)(2-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)cyclopropyl) methanone (134);

(E)-1-(3-hydroxy-1H-indazol-1-yl)-3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)prop-2-en-1-one (142);

(3-hydroxy-1H-indazol-1-yl)(2-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl) cyclopropyl)methanone (146);

(E)-3-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)-N-(pyridin-3-yl)acrylamide (150); and pharmaceutically acceptable salts thereof.

[0013] In another example, provided are pharmaceutical compositions comprising any compound of the present disclosure (e.g., compound of Formula **I**, 2-[[(E)-3-[4-(cyclopropylmethyl)-3-methoxyphenyl]prop-2-enoyl]amino]benzoic acid)) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0014] In another example, provided are methods of disease or condition associated with fibrosis in a subject in need thereof, the method comprising administering any compound of the present disclosure (*e.g.*, compound of Formula **I**, 2-[[(E)-3-[4-(cyclopropylmethyl)-3-methoxyphenyl]prop-2-enoyl]amino]benzoic acid)) or a pharmaceutically acceptable salt thereof,

or a pharmaceutical composition comprising any compound of the present disclosure (*e.g.*, compound of Formula **I**, 2-[[(E)-3-[4-(cyclopropylmethyl)-3-methoxyphenyl]prop-2-enoyl]amino]benzoic acid)) or pharmaceutically acceptable salt thereof, to the subject. In certain examples, the disease or condition associated with fibrosis is selected from the group consisting of fibrotic skin disorders, lung disease, heart disease, kidney disease, and cirrhosis of the liver. In certain examples, the the disease or condition associated with fibrosis is kidney disease. In certain examples, the kidney disease is progressive kidney disease, glomerulonephritis, diabetic kidney disease, diabetic nephropathy, systemic lupus, primary glomerulonephritis, membranous nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, diffuse proliferative glomerulonephritis, membranous focal segmental glomerulosclerosis, secondary glomerulonephritis, or ischemic nephropathy. In certain examples, the disease or condition associated with fibrosis is focal segmental glomerulosclerosis.

[0015] In another example, provided are kits comprising any compound of the present disclosure (*e.g.*, compound of Formula **I**, 2-[[(E)-3-[4-(cyclopropylmethyl)-3-methoxyphenyl]prop-2-enoyl]amino]benzoic acid)) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any compound of the present disclosure (*e.g.*, compound of Formula **I**, 2-[[(E)-3-[4-(cyclopropylmethyl)-3-methoxyphenyl]prop-2-enoyl]amino]benzoic acid)) or pharmaceutically acceptable salt thereof. In certain examples, the kits further comprise instructions for administration (*e.g.*, human administration).

[0016] The details of certain embodiments of the invention are set forth in the Detailed Description of Certain Embodiments, as described below. Other features, objects, and advantages of the invention will be apparent from the Definitions, Examples, Figures, and Claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] *Figure 1* shows a pharmacokinetic profile plot (plasma concentration vs. time) after administration of 2 mg/kg, 20 mg/kg, 75 mg/kg, and 350 mg/kg of **116** to male SD rats.

[0018] *Figure 2* shows shows a pharmacokinetic profile plot (plasma concentration vs. time) after daily administration (5 days) of 75 mg/kg, and 350 mg/kg of **116** to male SD rats.

CLAIMS

What is claimed is:

1. A compound of Formula **I**:



I,

or a pharmaceutically acceptable salt thereof; wherein

T is  ;

X is O;

Y is O;

Z is a bond;

R^1 is C_{2-4} alkynyl;

R^2 is C_{1-4} alkyl;

R^3 is hydrogen, alkyl, alkynyl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein R^3 is optionally substituted with $-NR^aR^b$ or alkyl;

R^4 and R^5 are hydrogen;

each occurrence of R^6 is, independently, F, Cl, or Br;

G is hydrogen;

m is 1 or 2; and

each occurrence of R^a and R^b is, independently, hydrogen, acyl, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, heterocyclyl, $C(O)OC_{1-6}$ alkyl, $C(O)C_{1-6}$ alkyl, or R^a and R^b together with the atoms to which they are attached form a heterocyclyl ring.

2. A compound of Formula **I**:



I,

or a pharmaceutically acceptable salt thereof; wherein

T is  ;

X is O;

Y is O;

Z is a bond;

R^1 is C_{2-4} alkynyl;

R^2 is C_{1-4} alkyl;

R^3 is hydrogen, alkyl, alkynyl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein R^3 is optionally substituted with $-NR^aR^b$ or alkyl;

R^4 and R^5 are hydrogen;

G is $C(O)R^7$;

R^7 is NHR^9;

m is 0;

R^9 is tetrazolyl, pyridinyl, pyrazolyl, imidazolyl, or triazolyl, each of which is optionally substituted with up to two alkyl groups; and

each occurrence of R^a and R^b is, independently, hydrogen, acyl, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, heterocyclyl, $C(O)OC_{1-6}$ alkyl, $C(O)C_{1-6}$ alkyl, or R^a and R^b together with the atoms to which they are attached form a heterocyclyl ring.

3. A compound of Formula **I-i**:



I-i,

or a pharmaceutically acceptable salt thereof; wherein

X is O or NR^{10};

Y is O or NR^{10};

each occurrence of R^g and R^h is, independently, hydrogen or alkyl, or R^g and R^h together with the carbon atom to which they are attached form a carbonyl;

t is 1 or 2; and

each occurrence of R^{10} is, independently, hydrogen or C_{1-4} alkyl.

4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein:

X is O;

Y is NR^{10}; and

R^{10} is C_{1-4} alkyl.

5. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein:

X is NR^{10}; and

Y is O.

6. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein:

R^g and R^h together with the carbon atom to which they are attached form a carbonyl.

7. The compound of claim 3, wherein the compound is of Formula **I-j**:



I-j,

or a pharmaceutically acceptable salt thereof,

wherein Y is NR^{10}; and R^{10} is C_{1-4} alkyl.

8. A compound selected from the group consisting of:
(E)-N-(2-fluorophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (1);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(5-methyl-1H-1,2,4-triazol-3-yl)phenyl)acrylamide (2);
(E)-N-(2-chlorophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (3);
(E)-N-(2-bromophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (4);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(o-tolyl)acrylamide (5);
(E)-N-(2-cyanophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (6);
(E)-N-(3,4-dichlorophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (7);
(E)-N-(2-(2H-tetrazol-5-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (16);
(E)-N-(2-(1,2,4-oxadiazol-3-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (17);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)-acrylamide (18);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)acrylamide (19);
(E)-N-(2-(1,2,4-oxadiazol-5-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (20);
(E)-N-(2-(1,3,4-oxadiazol-2-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (21);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(1-methyl-1H-pyrazol-4-yl)phenyl)-acrylamide (22);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)acryl-amide (23);
(E)-N-(2-(1H-pyrazol-4-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (24);
(E)-N-(2-(1H-imidazol-4-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (25);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(1-methyl-1H-imidazol-4-yl)phenyl)acrylamide (26);

(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(methylsulfonyl)benzamide (27);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)acryl-amide (28);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-acrylamide (29);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2H-tetrazol-5-yl)benzamide (31);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(1-methylpiperidin-4-yl)benzamide (36);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(oxetan-3-yl)benzamide (38);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(pyridin-4-yl)benzamide (44);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(1-methyl-1H-pyrazol-4-yl)benzamide (47);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(1-methyl-1H-pyrazol-3-yl)benzamide (48);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(piperidin-4-yl)benzamide (49);
(E)-2-(3-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamido)benzoic acid (51);
(E)-N-(3-cyanophenyl)-3-[2-[2-(dimethylamino)ethoxy]-3-methoxy-4-prop-2-ynoxy-phenyl]prop-2-enamide (76);
((E)-N-(2-cyanophenyl)-3-(2-(2-(dimethylamino)ethoxy)-3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (77);
(E)-2-(3-(2-(2-(dimethylamino)ethoxy)-3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-benzoic acid (78);
(E)-N-(2-cyanophenyl)-3-[3-methoxy-2-(1-methylazetidin-3-yl)oxy-4-prop-2-ynoxy-phenyl]prop-2-enamide (79);
2-[[(E)-3-(3-methoxy-4-prop-2-ynoxy-2-pyrrolidin-3-yloxyphenyl)prop-2-enoyl]amino]benzoic acid (80);
(E)-N-(2-cyanophenyl)-3-[3-methoxy-2-(1-methylpyrrolidin-3-yl)oxy-4-prop-2-ynoxy-phenyl]prop-2-enamide (81);

(E)-N-(2-cyanophenyl)-3-(3-methoxy-4-prop-2-ynoxy-2-pyrrolidin-3-yloxy-phenyl)prop-2-enamide (82);
2-[[(E)-3-[3-methoxy-2-(4-piperidyloxy)-4-prop-2-ynoxy-phenyl]prop-2-enoyl]amino]benzoic acid (83);
2-[[(E)-3-[3-methoxy-2-(2-morpholinoethoxy)-4-prop-2-ynoxy-phenyl]prop-2-enoyl]amino]benzoic acid (84);
(E)-N-(2-cyanophenyl)-3-[3-methoxy-2-(2-morpholinoethoxy)-4-prop-2-ynoxy-phenyl]prop-2-enamide (85);
2-[[(E)-3-[2-[3-(dimethylamino)propoxy]-3-methoxy-4-prop-2-ynoxy-phenyl]prop-2-enoyl]amino]benzoic acid (86);
(E)-N-(2-cyanophenyl)-3-[2-[3-(dimethylamino)propoxy]-3-methoxy-4-prop-2-ynoxy-phenyl]prop-2-enamide (87);
(E)-N-(2-cyanophenyl)-3-[3-methoxy-2-(4-piperidyloxy)-4-prop-2-ynoxy-phenyl]prop-2-enamide (88);
(E)-N-(2-cyanophenyl)-3-[3-methoxy-2-[(1-methyl-4-piperidyl)oxy]-4-prop-2-ynoxy-phenyl]prop-2-enamide (89);
2-[[(E)-3-[4-(cyclopropylmethoxy)-2-[2-(dimethylamino)ethoxy]-3-methoxy-phenyl]prop-2-enoyl]amino]benzoic acid (90);
(E)-N-(3-cyanophenyl)-3-(2-(2-(dimethylamino)ethoxy)-3-methoxyphenyl)acrylamide (91);
(E)-N-(2-cyanophenyl)-3-(2-(2-(dimethylamino)ethoxy)-3-methoxyphenyl)acrylamide (92);
(E)-N-(3-cyanophenyl)-3-(2-(2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamide (93);
(E)-N-(2-cyanophenyl)-3-[2-[2-(dimethylamino)ethoxy]-4-methoxy-phenyl]prop-2-enamide (94);
(E)-2-(3-(3,4-dimethoxy-2-(prop-2-yn-1-yloxy)phenyl)acrylamido)benzoic acid (95);
(E)-2-(3-(3,4-dimethoxy-2-(pyridin-3-ylmethoxy)phenyl)acrylamido)benzoic acid (96);
(E)-2-(3-(3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)acrylamido)benzoic acid (97);
(E)-2-(3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamido)benzoic acid (98);
(E)-2-(3-(3-methoxy-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamido)benzoic acid (99);
(E)-2-(3-(4-methoxy-3-morpholinophenyl)acrylamido)benzoic acid (101);
(E)-2-(3-(3-methoxy-4-morpholinophenyl)acrylamido)benzoic acid (103);

(E)-2-(3-(4-methoxy-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamido)benzoic acid (104);
2-[[(E)-3-(4-methyl-2,3-dihydro-1,4-benzoxazin-6-yl)prop-2-enoyl]amino]benzoic acid (107);
(E)-N-(2-(1,2,4-oxadiazol-5-yl)phenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (108);
(E)-2-(3-(4-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)acrylamido)benzoic acid (109);
(E)-2-(3-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)acrylamido)benzoic acid (110);
(E)-2-(3-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acrylamido)benzoic acid (111);
(E)-2-(3-(4-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acrylamido)benzoic acid (112);
(E)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-acrylamide (114);
(E)-2-(3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)acrylamido)benzoic acid (116);
(E)-4-chloro-2-(3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)acrylamido)benzoic acid (117);
(E)-N-(4-fluorophenyl)-3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamide (120);
N-(4-cyanophenyl)-2-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)cyclopropane carboxamide (121);
2-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)-N-(4-fluorophenyl)cyclopropane-1-carboxamide (122);
(E)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-fluorophenyl)acrylamide (123);
(*E*)-*N*-(4-cyanophenyl)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (124);
(E)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)-N-(4-fluorophenyl)acrylamide (125);
(E)-3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)-N-(2-fluorophenyl)acrylamide (127);
(E)-3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)-N-(4-fluorophenyl)acrylamide (128);
(E)-N-(4-cyanophenyl)-3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)acrylamide (129);
(E)-2-(3-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)acrylamido)benzoic acid (130);
(E)-N-(4-cyanophenyl)-3-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide (131);
(E)-N-(4-fluorophenyl)-3-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide (132);

N-(4-fluorophenyl)-2-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)cyclopropanecarboxamide (133);
N-(4-cyanophenyl)-2-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)cyclopropanecarboxamide (135);
N-(4-fluorophenyl)-2-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)cyclopropane-1-carboxamide (136);
N-(4-cyanophenyl)-2-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)cyclopropane-1-carboxamide (137);
N-(2-fluorophenyl)-2-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)cyclopropane carboxamide (138);
(E)-N-(4-cyanophenyl)-3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamide (139);
(E)-3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-N-(2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)acrylamide (140);
(E)-N-(2-fluorophenyl)-3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)acrylamide (141);
N-(4-fluorophenyl)-2-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)cyclopropane carboxamide (143);
2-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-N-(2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)cyclopropanecarboxamide (144);
N-(2-fluorophenyl)-2-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)cyclopropane carboxamide (145);
(E)-N-(3-chlorophenyl)-3-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)acrylamide (147);
N-(3-chlorophenyl)-2-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)cyclopropane-1-carboxamide (148);
N-(4-chlorophenyl)-2-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)cyclopropane-1-carboxamide (149);
(E)-N-(3-chlorophenyl)-3-(4-methoxy-3-morpholinophenyl)acrylamide (151);
(E)-N-(2-chlorophenyl)-3-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)acrylamide (152);
(E)-N-(4-chlorophenyl)-3-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)acrylamide (153);

N-(4-chlorophenyl)-2-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)cyclopropane-1-carboxamide (154);
N-(2-chlorophenyl)-2-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)cyclopropane-1-carboxamide (155);
N-(3-chlorophenyl)-2-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)cyclopropane-1-carboxamide (156);
N-(2-chlorophenyl)-2-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)cyclopropane-1-carboxamide (157);
2-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)-N-(3-(methylsulfonyl)phenyl) cyclopropane-1-carboxamide (158);
(E)-N-(2-chlorophenyl)-3-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)acrylamide (159);
(E)-N-(3-chlorophenyl)-3-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)acrylamide (160);
(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-phenylacrylamide (8);
methyl (E)-1-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acryloyl)-1,2,3,4-tetrahydroquinoline-4-carboxylate (9)
(E)-1-(3,4-dihydroquinolin-1(2H)-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (10);
(E)-1-(3,4-dihydroquinoxalin-1(2H)-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (11);
(E)-1-(2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (12);
(E)-N-((trans)-2-aminocyclohexyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (13);
(E)-1-(4-hydroxy-3,4-dihydroquinolin-1(2H)-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (14);
(E)-1-(3-hydroxy-1H-indazol-1-yl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (15);
(E)-N-(2-(dimethylamino)ethyl)-2-(3-(3-methoxy-4-(prop-2-yn 1yloxy) phenyl) acrylamido) benzamide (30);

(E)-N-(3-(dimethylamino)propyl)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido) benzamide (32);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2-methoxyethyl)benzamide (33);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzamide (34);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2-morpholino ethyl)benzamide (35);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-((1-methylpiperidin-4-yl)methyl)benzamide (37);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-((tetrahydrofuran-3-yl)methyl)benzamide (39);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-((1-methyl-1H-imidazol-5-yl)methyl)benzamide (40);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(pyridin-2-ylmethyl)benzamide (41);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2-(pyridin-2-yl)ethyl)benzamide (42);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(pyridin-3-ylmethyl)benzamide (43);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(pyridin-4-ylmethyl)benzamide (45);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2-(pyridin-4-yl)ethyl)benzamide (46);
(E)-2-(3-(3-methoxy-4-(piperidin-4-ylmethoxy)phenyl)acrylamido)benzoic acid (50);
(E)-2-(3-(4-((3,5-dimethylisoxazol-4-yl)methoxy)-3-methoxyphenyl)acrylamido)benzoic acid (52);
(E)-2-(3-(3-methoxy-4-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)acrylamido)benzoic acid (53);
(E)-2-(3-(3-methoxy-4-(oxetan-3-ylmethoxy)phenyl)acrylamido)benzoic acid (54);
(E)-2-(3-(3-methoxy-4-(2-(pyridin-2-yl)ethoxy)phenyl)acrylamido)benzoic acid (56);

(E)-2-(3-(3-methoxy-4-(2-(pyridin-3-yl)ethoxy)phenyl)acrylamido)benzoic acid (57);
(E)-2-(3-(3-methoxy-4-(2-(pyridin-4-yl)ethoxy)phenyl)acrylamido)benzoic acid (59);
(E)-2-(3-(3-methoxy-4-((1-methyl-1H-pyrazol-5-yl)methoxy)phenyl)acrylamido)benzoic acid (60);
(E)-2-(3-(4-methoxy-3-(2-methoxyethoxy)phenyl)acrylamido)benzoic acid (61);
(E)-2-(3-(4-methoxy-3-(2-(pyridin-2-yl)ethoxy)phenyl)acrylamido)benzoic acid (62);
(E)-2-(3-(4-methoxy-3-(pyridin-3-ylmethoxy)phenyl)acrylamido)benzoic acid (63);
(E)-2-(3-(4-methoxy-3-(2-(pyridin-3-yl)ethoxy)phenyl)acrylamido)benzoic acid (64);
(E)-2-(3-(4-methoxy-3-(2-(pyridin-4-yl)ethoxy)phenyl)acrylamido)benzoic acid (65);
(E)-2-(3-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)acrylamido)benzoic acid (66);
(E)-2-(3-(4-methoxy-3-((1-methyl-1H-pyrazol-5-yl)methoxy)phenyl)acrylamido)benzoic acid (67);
(E)-2-(3-(3-methoxy-4-((4-methylpiperazin-1-yl)methyl)phenyl)acrylamido)benzoic acid (68);
(E)-2-(3-(3-methoxy-4-(morpholinomethyl)phenyl)acrylamido)benzoic acid (69);
(E)-2-(3-(4-methoxy-3-(((1-methylpiperidin-4-yl)oxy)methyl)phenyl)acrylamido)benzoic acid (70)
(E)-2-(3-(4-methoxy-3-((prop-2-yn-1-yloxy)methyl)phenyl)acrylamido)benzoic acid (71);
(E)-2-(3-(3-methoxy-4-((prop-2-yn-1-yloxy)methyl)phenyl)acrylamido)benzoic acid (72);
(E)-2-(3-(4-methoxy-3-(methoxymethyl)phenyl)acrylamido)benzoic acid (73);
(E)-2-(3-(4-methoxy-3-((prop-2-yn-1-ylamino)methyl)phenyl)acrylamido)benzoic acid (74);
(E)-2-(3-(3-methoxy-4-((prop-2-yn-1-ylamino)methyl)phenyl)acrylamido)benzoic acid (75);
(E)-2-(3-(4-ethyl-3-methoxyphenyl)acrylamido)benzoic acid (100);
2-[[(E)-3-[4-(cyclopropylmethyl)-3-methoxyphenyl]prop-2-enoyl]amino]benzoic acid (102);
(E)-2-(3-(3-ethyl-4-methoxyphenyl)acrylamido)benzoic acid (105);
(E)-2-(3-(3-(cyclopropylmethyl)-4-methoxyphenyl)acrylamido)benzoic acid (106);
(E)-1-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (113);
(E)-1-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-3-(2-(2-(dimethylamino)ethoxy)-3,4-dimethoxyphenyl)-prop-2-en-1-one (115);

(E)-1-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-3-(3-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)prop-2-en-1-one (118);
(2H-benzo[b][1,4]oxazin-4(3H)-yl)(2-(3-methoxy-4-(prop-2-yn-1-yloxy) phenyl) cyclopropyl) methanone (119);
(E)-3-(3-ethyl-4-(prop-2-yn-1-yloxy)phenyl)-1-(3-hydroxy-1H-indazol-1-yl)prop-2-en-1-one (126);
(3-hydroxy-1H-indazol-1-yl)(2-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)cyclopropyl) methanone (134);
(E)-1-(3-hydroxy-1H-indazol-1-yl)-3-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)prop-2-en-1-one (142);
(3-hydroxy-1H-indazol-1-yl)(2-(3-methoxy-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl) cyclopropyl)methanone (146);
(E)-3-(4-methoxy-3-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)-N-(pyridin-3-yl)acrylamide (150); and pharmaceutically acceptable salts thereof.

9. The compound of claim 8, selected from the group consisting of:
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(2H-tetrazol-5-yl)benzamide (31);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-((1-methyl-1H-imidazol-5-yl)methyl)benzamide (40);
(E)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)-N-(pyridin-4-ylmethyl)benzamide (45);
2-[[(E)-3-(4-methyl-2,3-dihydro-1,4-benzoxazin-6-yl)prop-2-enoyl]amino]benzoic acid (107);
(E)-2-(3-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)acrylamido)benzoic acid (110);
(E)-2-(3-(4-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acrylamido)benzoic acid (112); and pharmaceutically acceptable salts thereof.

10. A pharmaceutical composition comprising the compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. The compound of any one of claims 1-9 or a pharmaceutically acceptable salt thereof, or

the pharmaceutical composition of claim 10 for use in therapy.

12. Use of the compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 10 in the manufacture of a medicament for treating a disease or condition associated with fibrosis in a subject in need thereof.

13. The use of claim 12, wherein the disease or condition is selected from the group consisting of fibrotic skin disorders, lung disease, heart disease, kidney disease, and cirrhosis of the liver.

14. The use of claim 13, wherein the disease or condition is kidney disease.

15. The use of claim 14, wherein the kidney disease is progressive kidney disease, glomerulonephritis, diabetic kidney disease, diabetic nephropathy, systemic lupus, primary glomerulonephritis, membranous nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, diffuse proliferative glomerulonephritis, membranous focal segmental glomerulosclerosis, secondary glomerulonephritis, or ischemic nephropathy.

16. The use of claim 14, wherein the kidney disease is focal segmental glomerulosclerosis.